Important recall: Selected Omnipod® 5 and Omnipod DASH® Pods 27 May 2026 Insulet has issued a critical recall affecting specific lots of Omnipod 5 and Omnipod DASH Pods after identifying a manufacturing issue through routine product monitoring. The issue relates to a small tear that may occur in the Pod’s cannula (tubing), just above the skin. If this happens, insulin may leak outside the Pod instead of being fully delivered into the body, which can result in less insulin being delivered than intended. People using an affected Pod may notice signs such as moisture on the skin or Pod adhesive, or the smell of insulin. However, in some cases, the leak may not be obvious. This means blood glucose levels may rise and may not respond as expected to insulin delivery. While users of Omnipod 5 in Automated Mode may receive an alert, this issue can also occur without any notification, so it’s important not to rely solely on Pod alerts. Affected lots include: Omnipod® 5: PH1U10212421 Omnipod DASH®: PD1U09042421, PD1U11122421, PD1U11202421 Reduced insulin delivery can lead to high blood glucose levels (hyperglycaemia). In more serious cases, prolonged high blood glucose can lead to diabetic ketoacidosis (DKA), a life-threatening condition that requires urgent medical treatment. Globally, there have been 24 reports of serious adverse events, including hospitalisation and DKA. There have been no reported deaths and no serious adverse events reported in Australia. This issue does not affect continuous glucose monitoring (CGM) systems or CGM readings. Insulet has identified the cause of the problem and implemented corrective actions. Pods that are not included in the affected lots remain safe to use, and supply is not expected to be disrupted. Impacted customers are being contacted directly with instructions on how to check lot numbers, stop using affected Pods, and arrange free replacements. If you think your Pods may be affected, stop using them immediately and switch to a Pod from an unaffected lot. For support, contact Insulet Product Support on 1800 954 074 (available 24/7), or speak with your healthcare professional.
Media releases 7 July 2026 Sights set on deadlier vision across the Territory More Aboriginal and Torres Strait Islander people living with diabetes across the Northern Territory will be supported to protect their sight through a new partnership between Diabetes Australia and Deadly Vision Centre. Continue Reading
Blog 6 July 2026 Running with purpose: Brodie’s mission to redefine type 1 diabetes In this motivating episode of Life on the level, Brodie opens up about carving a path from country kid to a global role model for others with type 1 diabetes. Continue Reading
News 3 July 2026 Daonil to be discontinued in Australia People living with type 2 diabetes who use Daonil are encouraged to speak with their doctor or diabetes healthcare team... Continue Reading